Leerink Partners and Cantor are acting as joint book-running managers for the offering. Eledon currently intends to use the net proceeds from the proposed offering to support the continued clinical ...

Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co., Truist Securities and LifeSci Capital are acting as ...

The company's shares (LLY) climbed 2.5% in afternoon trading on Tuesday, after closing at a record high of $966.64 on Monday. That rally pushed Lilly's market capitalization up to $937 billion, ...

Investing.com -- Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.

Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...

Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of uniQure N.V. (NasdaqGS:QURE) with a ...

Eli Lilly and Company is positioned for substantial growth following significant regulatory and strategic developments.

Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of Cogent Biosciences (NasdaqGS:COGT) with a ...